US · Healthcare · Drug Manufacturers - General
EPS came in at 3.65 against a street estimate of 3.64 — a beat of 0.3%.
Analysts rate AbbVie Inc a buy (16 buy, 12 hold, 0 sell out of 28) with an average price target of $270.39.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.53% |
| Vanguard Capital Management, LLC | 6.50% |
| State Street Corp | 4.60% |
| JPMorgan Chase & Co | 3.21% |
| Vanguard Portfolio Management, LLC | 2.80% |
| Geode Capital Management, LLC | 2.65% |
| Morgan Stanley - Brokerage Accounts | 2.15% |
| Capital Research Global Investors | 1.77% |
| Document | Date |
|---|---|
| Results announced · Q3 2026 | 2026-07-31 |
| Results announced · Q3 2026 | 2026-07-06 |
| Reg FD disclosure · Q2 2026 | 2026-06-22 |
| Shareholder vote results · Q2 2026 | 2026-05-12 |
| Quarterly report · Q1 2026 | 2026-05-08 |
| Proxy statement · Q2 2026 | 2026-03-23 |
| Annual report FY2025 | 2026-02-20 |
| Quarterly report · Q3 2025 | 2025-11-04 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $1.73 / share ex-date Jul 15, 2026 · pay Aug 14, 2026 | 2026-07-15 |
| Dividend | $1.73 / share ex-date Apr 15, 2026 · pay May 15, 2026 | 2026-04-15 |
| Dividend | $1.73 / share ex-date Jan 16, 2026 · pay Feb 17, 2026 | 2026-01-16 |
| Dividend | $1.64 / share ex-date Oct 15, 2025 · pay Nov 14, 2025 | 2025-10-15 |
| Dividend | $1.64 / share ex-date Jul 15, 2025 · pay Aug 15, 2025 | 2025-07-15 |
| Announcement | Date |
|---|---|
| Full-year 2026 adjusted diluted earnings per share guidance range updated AbbVie announced that Q2 2026 earnings will include a $291 million pre-tax charge for acquired IPR D (In-Process Research & Development) and milestone expenses related to licensing agreement | 2026-07-06 |
| Definitive agreement to acquire Apogee Therapeutics announced AbbVie Inc. announced on June 22, 2026, that it has signed a definitive agreement to acquire Apogee Therapeutics, Inc. This is a strategic acquisition in the pharmaceutical sector. Key Deta | 2026-06-22 |
| 2026 full-year and Q1 adjusted diluted earnings per share guidance updated AbbVie announced a one-time charge of $744 million in Q1 2026 related to acquired in-process R&D (IPR&D) and milestone payments from licensing deals and asset acquisitions. This charge reduc | 2026-04-03 |
| Full-year 2025 adjusted diluted EPS guidance range updated to $9.90-$9.94 AbbVie announced a $1.3 billion expense in Q4 2025 related to acquired intellectual property rights, development costs, and milestone payments from business collaborations and acquisitions. | 2026-01-07 |
| Full-year 2025 adjusted diluted EPS guidance range updated to $10.38-$10.58 AbbVie announced that Q3 2025 results will include a $2.7 billion pre-tax charge for acquired in-process R&D (IPR&D) and milestone expenses related to collaborations, licensing agreements, a | 2025-10-03 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for AbbVie Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.